Overview

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate whether intravenous administration (injected into a vein) of acetylsalicylic acid (Aspirin) in doses of 250 and 500 mg is superior to oral treatment of ACS with tablets containing 300 mg of Aspirin.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Acetylsalicylic acid lysinate
Aspirin